Therapeutic compounds and uses thereof
The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 3 -R 6 , X, and each R e have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
1. A compound of formula (I), or a salt thereof:
wherein:
R 1 is selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and carbocyclyl;
R 3 is selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and carbocyclyl;
and the group:
is selected from the group consisting of:
provided that when R 1 is methyl, R 3 is methyl, X is N(H), R 4 is H, R 6 is H and each Re is CH 3 ;
then R 5 is not phenyl; and
provided the compound is not:
or a salt thereof.
2. The compound of claim 1 wherein the group:
is selected from the group consisting of:
3. The compound or salt of claim 1 , which is selected from the group consisting of:
or a salt thereof.
4. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof
and a pharmaceutically acceptable adjuvant, carrier, or vehicle.
5. A method for treating ovarian cancer or renal cell carcinoma in an animal comprising administering to the animal a compound of claim 1 or a pharmaceutically acceptable salt thereof.
6. A method of treating ovarian cancer or renal cell carcinoma in an individual comprising administering to the individual (a) a compound of claim 1 or a pharmaceutically acceptable salt thereof, and (b) a cytotoxic agent.
7. The compound of claim 1 , wherein R 1 is methyl.
8. The compound of claim 1 , wherein R 3 is methyl.
9. A method of treating ovarian cancer or renal cell carcinoma in an animal comprising administering to the animal a compound of formula:
or a pharmaceutically acceptable salt thereof.